|Last Price$185.64||Day Change (%)-1.06%|
|Open Price$186.24||Day Change ($)-1.98|
|Day Range184.95–187.34||52-Week Range127.69–213.33|
As of Tue 3/31/2015 5:00:00 PM | USD
Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents
Illumina Launches TruSight HLA Solution
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer
Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...
Continued technology advancements and market expansion support Illumina's narrow moat.
Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.
Caren Mason Appointed President & CEO of STAAR Surgical Company
Recent deals have been driven more by tax strategies than therapeutic synergies.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.
Ownership data provide a look at who else owns the company.